Liver fibrosis is a significant precursor to cirrhosis and liver cancer, yet effective treatments remain elusive. Our previous studies demonstrated that Bletilla striata polysaccharide (BSP) has therapeutic effects, though it performed poorly at medium concentrations. To address this limitation, BSP underwent selenization modification. In this study, selenized BSP (Se-BSP) was structurally characterized, and its in vivo activity in alleviating liver fibrosis was evaluated. The results showed that the molecular weight of Se-BSP increased, its in vitro antioxidant activity improved, and it exhibited enhanced efficacy in alleviating liver fibrosis at medium concentrations (150 mg/kg) compared to BSP. These findings provide a theoretical basis for the potential application of Se-BSP as an anti-liver fibrosis agent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijbiomac.2025.140234 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploration of the Combined Mechanism of Direct and Indirect Effects of Paeoniflorin in the Treatment of Cholestasis.
Inflammation
January 2025
Department of Pharmacy, Chinese PLA General Hospital, Beijing, China.
Cholestasis is a multifactorial hepatobiliary disorder, characterized by obstruction of bile flow and accumulation of bile, which in turn causes damage to liver cells and other tissues. In severe cases, it can result in the development of life-threatening conditions, including cirrhosis and liver cancer. Paeoniflorin (PF) has been demonstrated to possess favourable therapeutic potential for the treatment of cholestasis.
View Article and Find Full Text PDFGut microbes associated with functional cure of chronic hepatitis B.
Hepatol Int
January 2025
Department of Virology II, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo, 162-8640, Japan.
Background And Aims: Hepatitis B virus (HBV) is prevalent worldwide and is difficult to eradicate. Current treatment strategies for chronic hepatitis B ultimately seek to achieve functional cure (FC); however, the factors contributing to FC remain unclear. We aimed to investigate the gut microbiota profiles of patients with chronic hepatitis B who achieved FC.
View Article and Find Full Text PDFAbbreviated Duration of Vasoactive Agents Has Similar Outcomes as Standard Duration of Therapy in Patients with Liver Cirrhosis and Variceal Bleeding: An Individual Patient Data Meta-Analysis.
Dig Dis Sci
January 2025
Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India.
Background: This two-stage individual patient data meta-analysis (IPD-MA) compared the efficacy of a shorter duration (≤ 2 days) of vasoactive (VA) drug therapy to standard duration (3-5 days) after acute variceal bleeding (AVB) in patients with liver cirrhosis.
Patients And Methods: Randomized clinical trials on patients with cirrhosis and AVB undergoing endoscopic band ligation which compared a short duration versus the standard duration of VA therapy were included. The primary outcome was 5-day rebleeding rate.
The Changing pathogenesis of liver cancer in Hawaii over three decades.
Cancer Epidemiol Biomarkers Prev
January 2025
Queen's Medical Center, Honolulu, HI, United States.
Background: Worldwide trends support the increasing contribution of hepatic steatosis on the incidence of hepatocellular carcinoma (HCC). This study investigates if similar changes are seen in Hawaii, where the incidence of HCC is higher than most of the United States. Methods; This is a retrospective study of 1651 patients diagnosed with HCC (1991-2023) that includes 60-70% of Hawaii's HCC cases.
View Article and Find Full Text PDFTrends in surgical volume and mortality by surgery type among patients with cirrhosis: A veterans affairs study.
Liver Transpl
January 2025
Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!